Tumour Cell Detection in Bone Marrow of Breast Cancer Patients
Author Information
Author(s): N. Harbeck, M. Untch, L. Pachel, W. Eiermann
Primary Institution: Klinikum Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany
Hypothesis
Can detecting tumour cells in the bone marrow of primary breast cancer patients predict relapse risk?
Conclusion
Detecting tumour cells in the bone marrow identifies high-risk breast cancer patients who may need additional therapy.
Supporting Evidence
- 38% of patients had tumour cells detected in their bone marrow.
- 39% of tumour cell-positive patients relapsed compared to 15% of tumour cell-negative patients.
- The median interval between tumour cell detection and relapse was 11.4 months.
- Relapse-free survival was significantly shorter in tumour cell-positive patients.
Takeaway
Doctors checked the bone marrow of breast cancer patients to see if there were any hidden cancer cells. Finding these cells helps them know which patients might get sick again.
Methodology
Bone marrow aspirates were taken from patients and analyzed using immunocytochemical techniques.
Potential Biases
Potential for false positives in tumour cell detection due to antibody specificity.
Limitations
The study may not account for all potential prognostic factors and had a limited follow-up period.
Participant Demographics
Patients aged 32 to 77 years, median age 54, with primary breast cancer.
Statistical Information
P-Value
p=0.0011
Confidence Interval
95%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website